Genmab says head and neck cancer drug cuts death risk by 50% with Merck’s Keytruda

ADRs climbed nearly 15% on Wednesday after the Danish drugmaker said that its bispecific antibody therapy, petosemtamab, in ...
BioPharma Dive

Genmab soars to record highs after cancer drug succeeds in key trial

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
ascopubs.org

Updated results of adjuvant toripalimab for locally advanced head and neck squamous cell carcinoma patients who achieved pathological complete response after neoadjuvant ...

Free flap surgery for oral squamous cell carcinoma: Postoperative complications and its association with oncologic outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
BIOENGINEER

ACOT7 fuels head and neck cancer growth by altering arachidonic acid and AKT-MDM2-p53 signaling

A new study reports that elevated ACOT7 promotes malignant phenotypes in head and neck squamous cell carcinoma by raising ...
Futurity

New clue hints at how head and neck cancers spread

"We have an important clue that increases our understanding of how head and neck cancers potentially behave and spread." ...
BIOENGINEER

Oral microbiome linked to postoperative delirium after head and neck cancer surgery

An exploratory study of 181 oral cancer patients links preoperative oral microbiome composition to postoperative delirium.
BioWorld

A three-armed activator of natural killer cells against head and neck squamous cell carcinoma

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...